Pharmafile Logo
Pharmafocus logo
Advanced Search
Manufacturing image

Manufacturing and production news in brief

September 6, 2013
Manufacturing and Production GSK, Jabones Pardo, Mylan, Shasun, Wockhardt

A round-up of pharma manufacturing facility news, with updates from Wockhardt, Mylan, GSK and Shasun, plus an FDA warning letter …

News
GSK lucozade image

GSK may sell Lucozade and Ribena to Japan’s Suntory

September 6, 2013
Sales and Marketing GSK, Suntory, lucozde, ribena

GSK is reportedly to sell its Lucozade and Ribena brands to Osaka-based Suntory in a deal worth up to £1.5 …

News
China image

China may be trying to ‘frighten’ pharma

September 6, 2013
Medical Communications, Sales and Marketing China, GSK, Sanofi, bribery

Western pharma companies caught up in Chinese probes over corruption are being discriminated against, according to a European business lobby …

News
Otsuka image

Otsuka buys Astex for $866 million

September 6, 2013
Sales and Marketing Astex, Lundbeck, Onyx, Otsuka

Otsuka Pharmaceutical is to buy UK-based Astex Pharmaceuticals in a deal that will see the Tokyo-based firm shelling out $866 …

News
george_toscano

NSF appoints senior director

September 6, 2013
Manufacturing and Production, Research and Development, Sales and Marketing NSF, Toscano

Public health organisation NSF International has appointed George Toscano as senior director of Quality Systems, Pharmaceuticals, Biotech and Biologics. Toscano …

Appointment

More cash for ‘paperless NHS’

September 5, 2013
Medical Communications, Sales and Marketing DoH, Hunt, NHS, paper free

The government has announced £1 billion funding for IT projects to help deliver its commitment to a paperless NHS by …

News
NICE image

NICE queries pharma R&D costs

September 5, 2013
Research and Development, Sales and Marketing Dillon, NICE, Pfizer, R&D

NICE has questioned whether pharma really spends as much as it says it does on bringing new treatments to market …

News
GSK image

GSK cancer vaccine fails in Phase III

September 5, 2013
Research and Development, Sales and Marketing BMS, GSK, Yervoy, melanoma, phase III

GlaxoSmithKline’s hopes of creating a cancer vaccine against the deadliest form of skin cancer took a blow today when its …

News
jamie_gault__novella

New leadership roles at Novella Clinical

September 5, 2013
Manufacturing and Production, Research and Development, Sales and Marketing CRO, novella clinical

Contract research organisation Novella Clinical has announced that three senior executives have assumed new leadership roles within the firm. Deborah …

Appointment
astrazeneca image

AstraZeneca begins olaparib programme

September 4, 2013
Sales and Marketing AstraZeneca, olaparib, ovarian cancer

AstraZeneca has begun recruitment in its Phase III programme for olaparib, a potential first-in-class oral poly ADP ribose polymerase (PARP) …

News
Brain image

Transparent implant opens ‘window’ on the brain

September 4, 2013
Medical Communications, Research and Development, Sales and Marketing UC, YSZ, brain

Researchers have developed a cranial implant that could act as a brain ‘window’, making life-changing procedures safer and easier. The …

News
GSK China image

GSK faces new China allegations

September 4, 2013
Medical Communications, Sales and Marketing China, GSK, bribery

GlaxoSmithKline is facing a potential worsening of its already embarrassing situation in China, where the UK-based group has been accused …

News
chris_molley_web

RSA hires Chris Molloy as chief executive

September 4, 2013
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Chris Molley, rsa

Life sciences executive search and interim management firm RSA has announced the appointment of Chris Molloy as its chief executive. …

Appointment
Amgen image

Amgen/Cytokinetics heart drug fails in clinical trial

September 3, 2013
Research and Development, Sales and Marketing Amgen, Novartis, cytokinetics, omecamtiv mecarbil

A new heart failure drug by Amgen and Cytokinetics has fallen short of its primary endpoint in a Phase II …

News
Tafinlar image

GSK’s skin cancer pill Tafinlar gets EMA approval

September 3, 2013
Sales and Marketing BMS, GSK, Tafinlar, Yervoy, melanoma

GSK has been granted EMA marketing authorisation for its new metastatic melanoma drug Tafinlar. The EMA’s decision on Tafinlar (dabrafenib) …

News
Aubagio image

Aubagio approved in Europe

September 3, 2013
Sales and Marketing Aubagio, Genzyme, Rebif, Sanofi, tecfidera

Sanofi’s once-daily multiple sclerosis pill Aubagio has been authorised by European regulators, paving the way for it to continue its …

News
NICE image

Rare disease drugs ‘need separate budget’

September 3, 2013
Research and Development, Sales and Marketing NHS, NICE, rare diseases

A group of MPs in the UK are calling for a ring-fenced fund to pay for drugs for rare and …

News
Corden pharma image

CordenPharma gets bigger in peptides

September 3, 2013
Manufacturing and Production API, CordenPharma, Solvay, peptides

Solvay has reached an agreement to sell its peptide subsidiary Peptisyntha SA to the holding company behind contract manufacturing organisation …

News
Janssen image

Women in the pharma industry

September 3, 2013
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Janssen, Johnson and Johnson, adams, women

In the past pharma has been accused of being too male-orientated in both the laboratory and the boardroom. The idea …

Feature
herceptin image

EU green light for ‘new’ Herceptin

September 3, 2013
Sales and Marketing EU, Herceptin, Roche, breast cancer

 Roche has ticked another approval off Herceptin’s list with the news that the European Commission is allowing a new form …

News
The Gateway to Local Adoption Series

Latest content

Siemens Healthineers opens 10m euro R&D centre for laboratory equipment in Ireland

February 19, 2026

Everdrone announces new board of directors to drive expansion

February 19, 2026

Regeneron announces presentations of new data on Eylea HD for retinal disease

February 18, 2026

Indegene completes acquisition of Cake Health

February 18, 2026

Gedeon Richter UK acquires rights to schizophrenia treatment Reagila from Recordati Pharmaceuticals

February 17, 2026